Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the near-approval molecule to a significant improvement from baseline, but placebo performed similarly, triggering a 12% drop in Vertex’s share price in premarket trading.